{"a":[{"_":"FDA approves Freenome colorectal cancer blood test to be marketed by Abbott","$":{"href":"/medtech/fda-signs-freenomes-bowel-cancer-screener-abbott-preps-sell-blood-test-us","hreflang":"en"}}]}
RegulatoryapprovedSimpleScreen CRCPositive
AI Analysis
Summary
The FDA has approved Freenome's SimpleScreen CRC, a blood-based colorectal cancer screening test, which Abbott will exclusively market in the U.S. This regulatory approval enables commercialization of the non-invasive cancer detection diagnostic.
Outcome Details
FDA approved Freenome's SimpleScreen CRC blood-based colorectal cancer test
Importance:8/10
Sentiment:
0.85
FDA approvalblood testcolorectal cancerdiagnosticpartnership
Related Companies
Read the original article
Published by FierceBiotech on July 27, 2026 10:31 AM